Recently, Hefei CAS Ion Medical and Technical Devices Co., Ltd. (HFCIM) announced another achievement with the successful operation of their independently developed 240MeV high-energy medical superconducting cyclotron, which marks the fourth cyclotron produced by HFCIM, following the 200MeV cyclotron in 2020, the 14MeV cyclotron in 2021, and the first 240MeV cyclotron delivered to customers in 2023.

The successful operation of this cyclotron signifies that HFCIM has the standardized mass production capability for high-performance superconducting cyclotron. This achievement establishes a solid technological foundation for the industrialization of homemade proton therapy system.

During the development process, HFCIM has continuously carried out optimization work on the cyclotron, leading to a further improvement in the overall performance of the product. The cyclotron is now capable of meeting the requirements for rapid intensity-modulated radiotherapy (IMRT) and Flash therapy in cancer treatment. The team has consistently adhered to standardized production, ensuring product quality while significantly reducing the production cycle by nearly half. Next, HFCIM will promptly proceed with the on-site installation, acceptance testing, and delivery of the cyclotron to the customer.

Meanwhile, various preparatory tasks for the registration of the proton therapy system based on the 240MeV superconducting cyclotron are under progress. The proton therapy system has been fully installed at the Hefei Ion Medical Center and is about to undergo comprehensive testing and inspection.